Fig 2.

Somatic CTNNB1 mutations in patients with adrenocortical tumors (ACTs) without TP53 mutations. (A) Schematic diagram of activating CTNNB1 mutations. (B) Immunohistochemical analysis of β-catenin and yes-associated protein 1 (YAP1) in pediatric ACTs. YAP serves as a surrogate marker for β-catenin expression. Moderate nuclear immunostaining of (i) β-catenin and (ii) YAP in a tumor with the S45P mutation in CTNNB1. Strong nuclear immunoreactivity for (iii) β-catenin and (iv) YAP in a pediatric patient with unknown CTNNB1 molecular status. These results are indicative of Wnt signaling pathway activation. Size bars represent 50 μm. (C) Kaplan-Meier estimates for progression-free survival by CTNNB1 status (P = .80).